Breaking Down Zhejiang Tianyu Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ), founded in 1993, combines a clear mission to supply the highest-quality pharmaceutical products worldwide with a vision to contribute to human health and be the most reliable pharmaceutical enterprise, operating on a campus of more than 20 hectares and backed by certified quality, environmental and occupational health and safety systems; recognized as a model high-tech enterprise under China's Torch Program, Tianyu has passed GMP inspections from authorities in China, Japan and Korea and secured regulatory recognition for eight APIs through EUGMP Certificates or FDA EIR, while its core values - respect, innovation, cooperation and integrity - steer R&D, global manufacturing and partnerships that aim to build trust and expand the company's international footprint.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) - Intro

• Established: 1993
• Primary focus: APIs & pharmaceutical intermediates (R&D → manufacture → distribution)
• Manufacturing footprint: >20 hectares of production facilities
• Regulatory approvals: Passed GMP inspections by China, Japan, Korea and other regulators
• International certifications: Eight APIs holding EUGMP Certificates or FDA EIR
• Management systems: Quality, Environmental and Occupational Health & Safety systems certified
• Innovation recognition: Model high‑tech enterprise under China's Torch Program

• To advance global health by delivering high‑quality, reliable APIs and intermediates that enable safe, effective medicines.

• To be a leading global supplier of innovative APIs and intermediates, recognized for technical excellence, regulatory compliance and sustainable manufacturing.

• Quality first - uncompromising adherence to GMP and certified management systems.
• Innovation - continuous investment in R&D, process optimization and technology adoption.
• Compliance & integrity - proactive regulatory engagement and ethical business practices.
• Safety & sustainability - protecting people and the environment through certified systems.
• Customer focus - reliable supply and responsive partnerships with pharmaceutical manufacturers worldwide.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) - Overview

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) positions itself as a quality-driven pharmaceutical manufacturer with a clear mission to supply pharmaceutical products of the highest quality to the world. This mission has driven its product portfolio, manufacturing investments, regulatory compliance, and international market expansion.

Mission Statement

Tianyu's mission is to supply pharmaceutical products with the highest quality to the world. This commitment underscores the company's dedication to delivering safe and effective medications globally and reflects an unwavering focus on standards, trust, and long-term market leadership.

• Quality-first manufacturing: adherence to GMP, continuous quality control, and pharmacovigilance systems.
• Global reach: export channels and registration efforts in multiple regions to ensure worldwide availability.
• Trust & reliability: consistent product quality to build long-term partnerships with healthcare providers and distributors.

Vision

The company's vision is to be a leading global supplier of trusted pharmaceutical products, expanding therapeutic coverage while elevating standards of patient safety and manufacturing excellence.

• Scale international footprint through regulatory approvals and strategic partnerships.
• Expand R&D to address high-demand therapeutic areas and biosimilar opportunities.
• Leverage digital manufacturing and quality analytics to reduce defects and improve yield.

Core Values

• Patient safety - prioritizing safety in development, production, and post-market monitoring.
• Quality integrity - uncompromising standards across supply chain and manufacturing.
• Innovation - continuous improvement in product portfolio and production technologies.
• Responsibility - ethical conduct, environmental stewardship, and compliance.
• Collaboration - partnering with global distributors, research institutions, and healthcare providers.

Key Operational & Financial Metrics (Selected Years)

The table below summarizes representative recent-year financial and operational metrics to illustrate how the mission and values translate into measurable performance. Figures are presented in RMB millions unless otherwise noted.

How Mission Drives Capital Allocation & Strategy

• Higher R&D reinvestment: consistent increase in R&D spend (see table) to support quality-driven product development.
• Manufacturing upgrades: rising CapEx focused on quality systems, sterile production lines, and compliance with international standards.
• Global registration spend: resources directed toward overseas filings and distribution network expansion.

For an investor-focused breakdown of Zhejiang Tianyu Pharmaceutical Co., Ltd.'s financial condition and markets, see: Breaking Down Zhejiang Tianyu Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) - Mission Statement

• Commitment to patients: develop safe, effective medicines that address unmet medical needs.
• Quality-first manufacturing: ensure GMP-standard production and robust quality-control systems.
• Innovation-driven R&D: invest in new chemical entities and improved formulations to sustain long-term competitiveness.
• Stakeholder trust: uphold transparency, regulatory compliance, and ethical commercial practices.
• Global reach: expand international registration and distribution to make therapies accessible beyond China.

• Health impact: orient portfolio decisions toward high-burden therapeutic areas and chronic disease management.
• Reliability metrics: emphasize batch-release consistency, low recall rates, and timely supply chains.
• Innovation alignment: channel R&D spend to both lifecycle management and novel therapeutics to sustain pipeline renewal.
• Market presence: pursue regulatory approvals and commercial partnerships to broaden geographic reach.

• Corporate culture: embed patient-centric and quality-driven values into performance reviews and training.
• Governance: strengthen board oversight on compliance, pricing policy, and clinical ethics.
• Partnerships: collaborate with academic institutions, contract research organizations, and distributors to accelerate development and reach.
• ESG considerations: incorporate environmental controls in manufacturing, worker safety metrics, and transparent reporting.

• Pipeline prioritization: allocate capital to programs with the highest expected patient impact and commercial viability.
• Quality investments: modernize production lines, automation, and QC analytics to reduce variability and recalls.
• Global registration strategy: pursue WHO prequalification and regional approvals to open export markets.
• Talent and capability building: recruit regulatory, clinical, and GMP experts to sustain reliable operations.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) - Vision Statement

• Respect - valuing employees, patients and partners: Tianyu invests in talent development, occupational safety and inclusive workplace programs to retain expertise and drive operational excellence.
• Innovation - R&D as competitive engine: a sustained commitment to pharmaceutical research, formulation technology and product lifecycle management to expand therapeutic offerings and improve bioavailability and delivery.
• Cooperation - collaborative growth: strategic alliances with hospitals, distributors and research institutes to accelerate clinical development, market access and supply-chain resilience.
• Integrity - ethical compliance and transparency: strict quality control systems, regulatory compliance and investor disclosure practices to maintain trust across stakeholders.

• R&D intensity: prioritize allocation of resources to high-potential pipelines and platform technologies to increase new drug filings and generic-to-innovator transitions.
• Quality & compliance: continuous improvement in GMP sites, pharmacovigilance and third-party audits to reduce product risk and regulatory exposure.
• Commercial reach: targeted expansion in key therapeutic categories and geographic markets supported by data-driven marketing and channel partnerships.
• People & culture: programs for leadership development, cross-functional collaboration and employee engagement to embed respect and cooperation into daily operations.

• Board oversight: Ethics, compliance and R&D committees ensure decisions align with integrity and long-term value creation.
• KPIs tied to values: Performance incentives incorporate quality metrics, collaborative milestones and innovation outcomes.
• Transparent reporting: regular financial and ESG disclosures to stakeholders to demonstrate accountability and progress against the vision.